Abstract
Distal ulcerative colitis can be treated with oral or rectal mesalazine, or both. A foam enema preparation has been developed and its efficacy investigated. The aim of this study was to evaluate the efficacy and safety of mesalazine foam enemas compared with prednisolone foam enemas in the treatment of patients with acute distal ulcerative colitis. Patients aged over 18 years presenting with a relapse of distal ulcerative colitis were randomly allocated treatment with mesalazine foam enema (n= 149 evaluable patients) and prednisolone foam enema (n= 146 evaluable patients) for four weeks. A randomised multicentre investigator blind parallel group trial was conducted. It was found that after four weeks oftreatment, clinical remission was achieved by 52% of mesalazine treated patients and 31% of patients treated with prednisolone (p<O.OO1). There was a trend in favour of more patients in the mesalazine group achieving sigmoidoscopic remission (40Gb v 31%, p=O.10). Histological remission was achieved by 27% and 21% of patients receiving mesalazine and prednisolone respectively. Symptoms improved in both treatment groups. Significantly more mesalazine patients had no blood in their stools after four weeks of treatment (67% v 40/0, p<O.OO1). Prednisolone treated patients had significantly fewer days with liquid stools than mesalazine patients, with a median of 0 and 1 days respectively by week 4 (p=O.001). In this study mesalazine The protocol conformed to the Declaration of Helsinki and all amendments and was approved by the local ethics committees of all the participating hospitals. All the patients were informed of the nature and purpose of the study and gave their written consent.
The enrolment of patients by centre ranged from 1 to 32 with a median value of 6. Of the 337 patients screened 334 were randomised (167 in each treatment group), using a computer generated list prepared by SmithKline Beecham, to receive, at bedtime, over a four week period, either 2 g mesalazine foam enema, given rectally in two metered applications (total volume 120 ml) or 20 mg prednisolone foam enema given rectally in one metered application (total volume 30 ml). Both treatments were presented as blank cylindrical aerosol cans with disposable applicators, however, the prednisolone can was approximately half the size of the mesalazine cans. To maintain investigator blindness every effort was made to ensure they did not see the cans.
Patients were provided with loperamide capsules as escape antidiarrhoeal medication if clinically indicated.
At screening, patients were examined by flexible or rigid sigmoidoscopy or colonoscopy and a biopsy specimen taken to confirm the diagnosis. Safety was assessed by haematological (full blood count, platelets and erythrocyte sedimentation rate) and biochemical (urea, creatinine, albumin, bilirubin, alkaline phosphatase, serum aspartate aminotransaminase, and alanine aminotransferase) assessments at week 0 and week 4 and by recording of adverse events either observed by the investigator or reported by the patient at each follow up visit.
Statistical methods
Two hundred and eighty patients were required to complete the study assuming an 80% improvement with prednisolone compared with mesalazine. This sample size enabled significance testing at the 5% level to have an 80% probability of detecting a true difference between treatments of 15%.
Of the 334 patients randomised, 295 patients were included in the efficacy evaluable population. These patients had no major protocol violations and had received at least 11 days of randomised treatment. Thirty nine patients (18 in the 5-ASA group and 21 receiving prednisolone) were excluded from the analysis; the main reason being that they had received oral corticosteroid treatment or had changed the dose of their oral mesalazine/ sulphasalazine medication in the previous month (nine in the 5-ASA group and 17 receiving prednisolone). Other reasons for excluding data were that patients had Crohn's disease, were non-compliant, or had a normal sigmoidoscopy at entry.
Statistical analysis, by an extemal consultant, was performed using the MantelHaenszel x2 test (Table I) . Altogether 40 patients withdrew from the study, the main reason being lack of efficacy (five patients in the mesalazine group, 13 patients in the prednisolone group). A further three patients were excluded from the week 4 analysis for being outside of the specified visit window.
At entry all eligible patients had an abnormal sigmoidoscopy, the median grade was III. The median 'active inflammation score' was 7 in both treatment groups. Thus most patients had a moderately inflamed rectal mucosa (Table III) .
Efficacy assessments Table II shows that after four weeks patients in both treatment groups had improved sigmoidoscopically with a median in both groups of grade II. The median 'active inflammation score' was 2 in the mesalazine group and 3 in the prednisolone group. Clinical remission was achieved by significantly more patients treated with mesalazine than with prednisolone (52% v 31 % p<0-001) (Figure) . The 95% confidence intervals (CI) indicate that the treatment difference may be between 1 0% and 32% in favour of mesalazine.
There was no statistically significant difference between treatment groups in terms of sigmoidoscopic remission or histological remission. However, for both assessments there was a trend in favour of patients treated with mesalazine; for sigmoidoscopic remission 40% v 31% (p=0l10) and for histological remission 27% v 21% (p>0 2) (see Figure) .
Summary data recorded at week 4 showed that symptoms improved for patients in both treatment groups with no statistically significant differences except for blood in the stools (see Table III ). Mesalazine patients were statistically significantly less likely to have blood in the stools after four weeks of treatment, 67% V 40% had no blood (p<0-001), the 95% CI indicate that the treatment difference may be between 16% and 40% in favour of mesalazine. The diary card data confirmed the summary data and found a reduced number of days during week 4 with blood in the stools of patients treated with mesalazine foam enema (p<0001). Diary data also showed significantly fewer days with tenesmus in mesalazine recipients (p=0.038). Tenesmus occurred on two or more days in week 4 for 15% patients treated with mesalazine and for 29% patients treated with prednisolone.
Conversely, patients treated with prednisolone had significantly fewer days with abnormal stool consistency compared with mesalazine (p=0001). Abnormal stools occurred on three or more days in week 4 for 39% of patients treated with mesalazine compared with 23% of patients treated with prednisolone.
After four weeks of treatment 87% of mesalazine patients and 80% of prednisolone patients reported a global improvement in their symptoms (p=0O19), while 3% and 6% of patients respectively reported a global deterioration in symptoms.
Safety assessments
No clinically significant changes in haematological or biochemical parameters were noted. Both treatments were well tolerated.
As might be expected the most common adverse events affected the gastrointestinal tract, with abdominal pain and bloating being the most common (Table IV) .
Five patients withdrew from the study because of adverse events. Of the three patients withdrawn from the mesalazine group one suffered a pulmonary embolus, one had an elective prostatectomy, and the other had severe abdominal pain with rectal discharge. Only the last of these was considered drug related. The two prednisolone patients withdrawn for adverse events were due to a pulmonary embolus in one and eczema around the pubic area and back in the other, again only the second of these was considered related to study medication.
Discussion
Compared with topical prednisolone foam, mesalazine foam enema was associated with a significantly higher clinical remission rate, significantly fewer days with blood in the stools, and significantly fewer days of tenesmus and there were trends favouring better sigmoidoscopic and histological remission rates. Prednisolone foam enema on the other hand was found to produce significantly fewer days with abnormal stool consistency.
Over a longer treatment period we may have seen the trends favouring better sigmoidoscopic and histological remission in the mesalazine group become more significant as it has been shown in previous studies that histological improvement lags behind symptomatic improvement. 10 13 The extent of spread of the mesalazine foam enema used in this study has been investigated and found to disperse well into the descending colon and in some instances up to and beyond the splenic flexure (unpublished finding). Retrograde spread of enema preparations is dependent on enema volume and the larger volume of the mesalazine foam enema compared with the prednisolone enema (120 ml v 30 ml) may explain in part the greater efficacy seen in this study (all the commercially available corticosteroid foam enemas are of comparable volume).
Systemic absorption of mesalazine from the foam enema has been investigated and was found to be similar to that of other marketed mesalazine preparations (unpublished finding), suggesting the foam enema will be a safe and effective treatment for patients with ulcerative colitis.
The prolonged use of corticosteroid enemas including prednisolone foam enemas is undesirable as they are readily absorbed from the rectum and distal colon and are a potential cause of systemic side effects. A new mesalazine foam enema will therefore provide an effective alternative treatment without the side effects associated with the systemic absorption of corticosteroids.14 In conclusion mesalazine foam enema is a highly efficacious and well tolerated preparation for the treatment of patients with acute distal ulcerative colitis.
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